Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.81 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 3/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | OXTR | P30559 | 1/20 | 0.60 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.60 |
| ▸ | CD81 | P60033 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.55 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.55 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.55 |
| ▸ | PTPRC | P08575 | 2/20 | 0.55 |
| ▸ | PTPRF | P10586 | 2/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Barringtogenol C SCHEMBL15132635 | 1.00 | PTPN1 (0.81) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| Barringtogenol C SCHEMBL14871943 | 1.00 | PTPN1 (0.81) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL15883013 | 0.92 | PTPN1 (0.79) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL19360132 | 0.92 | PTPN1 (0.79) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL4324523 | 0.91 | PTPN1 (0.68) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL15132632 | 0.91 | PTPN1 (0.68) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL30222071 | 0.91 | PTPN1 (0.68) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL1050527 | 0.91 | PTPN1 (0.68) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL19284333 | 0.90 | PTPN1 (1.00) | PTPN1AKR1B10AKR1B1ALOX5F3 | |
| SCHEMBL29934333 | 0.90 | PTPN1 (1.00) | PTPN1AKR1B10AKR1B1ALOX5F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECH BV (NL) | 2025-09-25 | — | — | US | claimed |
| EP-4610278-A2 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | Sapreme Technologies B.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4452331-B1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | SAPREME TECH BV (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4591938-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-07-30 | — | — | EP | claimed |
| EP-4210760-B1 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | SAPREME TECH BV (NL) | 2025-06-18 | — | — | EP | claimed |
| EP-4529953-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-04-02 | — | — | EP | claimed |
| US-20250082759-A1 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2025-03-13 | — | — | US | claimed |
| CN-103509077-A | Triterpene saponin compound, its preparation method and applications | UNIV SHENYANG PHARMACEUTICAL | 2014-01-15 | — | — | CN | claimed |
| US-20130190538-A1 | PROCESS FOR THE PREPARATION OF PROTOESCIGENIN | WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) | 2013-07-25 | — | — | US | claimed |
| WO-2013055244-A1 | PREPARATION OF PROTOESCIGENIN FROM ESCIN | INSTYTUT FARMACEUTYCZNY (PL) | 2013-04-18 | — | — | WO | claimed |
| JP-4790620-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-7618946-B2 | Analgesic compounds, extracts containing same and methods of preparation | GRIFFITH UNIVERSITY (AU) | 2009-11-17 | — | — | US | claimed |
| US-20070270375-A1 | Novel Analgesic Compounds, Extracts Containing Same and Methods of Preparation | JARLMADANGAH BURU ABORIGINAL CORPORATION (AU) | 2007-11-22 | — | — | US | claimed |
| CN-1938326-A | Novel analgesic compounds, extracts containing same and methods of preparation | UNIV GRIFFITH (AU) | 2007-03-28 | — | — | CN | claimed |
| EP-1687320-A1 | NOVEL ANALGESIC COMPOUNDS, EXTRACTS CONTAINING SAME AND METHODS OF PREPARATION | GRIFFITH UNIVERSITY (AU) | 2006-08-09 | — | — | EP | claimed |
| WO-2005051969-A1 | NOVEL ANALGESIC COMPOUNDS, EXTRACTS CONTAINING SAME AND METHODS OF PREPARATION | GRIFFITH UNIVERSITY (AU) | 2005-06-09 | — | — | WO | claimed |
| CN-1568166-A | Coated stent for preventing restenosis | HEMOTEQ GMBH (DE) | 2005-01-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190538-A1 | PROCESS FOR THE PREPARATION OF PROTOESCIGENIN | PSAP, SEPTIN6, ESPL1 | PTPN1 3275/4885AKR1B10 1055/4885AKR1B1 2181/4885 |
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | PTPN1 485/4885AKR1B10 54/4885AKR1B1 59/4885 |
| US-20250082759-A1 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | MUSK, TNNC1, PYGM | PTPN1 2705/4885AKR1B10 3160/4885AKR1B1 2634/4885 |
| US-20070270375-A1 | Novel Analgesic Compounds, Extracts Containing Same and Methods of Preparation | DDOST, BBOX1, DAD1 | PTPN1 4182/4885AKR1B10 958/4885AKR1B1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.